CRVS as reported
- Net Income
- −$54M
Net Income · +20% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$45M
Free Cash Flow · +16% year on year · trailing twelve months to Q2 2026
- EPS
- −$0.61
EPS · −38% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$54M | +20% | Q2 2026 |
| EPS | −$0.61 | −38% | Q2 2026 |
| ROE | −22% | n/a | Q2 2026 |
| ROA | −20% | n/a | Q2 2026 |
| Free Cash Flow | −$45M | +16% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Corvus Pharmaceuticals, Inc. (CRVS) - Net IncomeNet IncomeCorvus Pharmaceuticals, Inc. (CRVS)
Biotechnology
Ranks #104 of 145 by Smart Score